This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
SPARC Site 03
Long Beach, California, United States
SPARC Site 05
Panorama City, California, United States
SPARC Site 01
DeLand, Florida, United States
SPARC Site 02
Orlando, Florida, United States
Adverse events
Time frame: 4 weeks
Peak plasma concentration
Time frame: 4 weeks
Area under the plasma concentration versus time curve
Time frame: 4 weeks
Time of observed peak plasma concentration
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
SPARC Site 04
Raleigh, North Carolina, United States